FDA grants accelerated approval for Bristol Myers Squibb’s Augtyro for NTRK-positive tumors
Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients 12 years and older with NTRK gene fusion-positive solid tumors. This approval, pivotal for patients with advanced stages of cancer where surgical options could cause severe morbidity, marks a significant advancement in targeted cancer therapy. Clinical Trial […]